Genmab — Juli 2023
-
Genmab (+2,3%, 2686) parternen Novartis øgede i andet kvartal salget af Kesimpta til 489 mio. dollar. Det svarer til en stigning på 105 pct. sammenlignet med salget i samme kvartal sidste år. Kesimpta til behandling af multipel sklerose er baseret på Genmabs virkemiddel Ofatumumab, og Genmab modtager 10 pct. af salget i royalties. Kilde: Landbobanken Børsnyt
-
Schweizisk Genmab-partner opjusterer efter overbevisende kvartal https://www.proinvestor.com/investornyt/1016615/schweizisk-genmab-partner-opjusterer-efter-overbevisende-kvartal
-
Novartis Q2 2023 Results
Investor
presentation https://www.novartis.com/sites/novartis_com/files/q2-2023-investor-presentation.pdf -
Q1: $386 mln, Q2: $489 mln og $873 mln for H123. Vi er vel over BB nu
https://www.novartis.com/sites/novartis_com/files/q2-2023-media-release-en.pdf side 5 -
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript https://www.proinvestor.com/investornyt/1017067/novartis-ag-nvs-q2-2023-earnings-call-transcript
-
Godmorgen
-
Spændende med J&J’s salgstal. Det plejer at være kl. ca. 12:30, de frigiver regnskabet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind